Pfizer’s proposed copay assistance program for its $225,000-a-year heart treatment would violate the Federal Anti-Kickback Statute (AKS).
Source: Drug Industry Daily
Pfizer’s proposed copay assistance program for its $225,000-a-year heart treatment would violate the Federal Anti-Kickback Statute (AKS).
Source: Drug Industry Daily